Most Popular

A Month of Tuberculosis Prophylaxis Works as Well as Nine Months for HIV Patients

A one-month antibiotic regimen to prevent active tuberculosis (TB) disease was at least as safe and effective as the standard nine-month therapy for people living with human immunodeficiency virus (HIV) infection, according to the results of a large international clinical trial. Adults and adolescents…

Drinking in Pregnancy May Harm More Children Than Thought

More children than previously thought may suffer from the health effects that can result when women drink alcohol while pregnant, according to researchers at the University of California San Diego School of Medicine. Their study, published online in the Journal of the American Medical Association, found…

FDA, Drug Compounder Trade Barbs in Shutdown Effort

The FDA’s bid to shut down an Arkansas drug compounder over allegations of “serious deficiencies” is drawing a heated response from the company owner, who says he’s fighting “a bureaucracy that makes broad claims against us, gives little feedback, and ignores independent third-party experts.”…

Biogen Ends Testing of Tysabri to Treat Strokes After Study Failure

Biogen Inc. says it will not develop natalizumab (Tysabri) for the treatment of acute ischemic stroke after the medication failed a phase 2b trial. Natalizumab, which made nearly $2 billion in 2017 sales, is part of Biogen’s franchise of multiple sclerosis (MS) drugs, a Reuters report noted. Biogen’s…

FDA Approves Lutathera for Some GEP-NETs

The FDA has approved lutetium Lu 177 dotatate (Lutathera, Advanced Accelerator Applications S.A.) for the treatment of somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. Lutathera, which received…

Report Shows Skyrocketing Costs for 20 Brand-Name Drugs

Prices for each of the 20 most-prescribed brand-name drugs for seniors have increased dramatically every year for the past five years, according to a new report released by U.S. Senator Claire McCaskill (D- Missouri). The cost of the drugs, which include brands like Advair (fluticasone propionate and…

Study Shows Far Broader Benefit for Thrombectomy After Stroke

Far more people than previously thought can benefit from an emergency procedure for acute ischemic stroke, according to a 38-center clinical trial sponsored by the National Institutes of Health and led by researchers at the Stanford University School of Medicine. The improved outcomes were achieved…

Worsening Flu Season Draws Comparisons to 2009 Pandemic

Just how bad a flu season are we having? Without a crystal ball, it’s impossible to predict the final toll. But just about any way you crunch the numbers, the prognosis is grim. “Most people with influenza are being infected with the H3N2 influenza virus. And in seasons where H3N2 is the main cause…

Take the Slow Boat To Healing

In Slow Medicine, Victoria Sweet, MD, pulls the reader into a different reality, one that harkens back to an earlier era of one-on-one medicine, when physicians and patients commonly shared a bond of trust and familiarity. That era has faded with the emergence of systems of care and performance targets.

Trulance Approved to Treat IBS with Constipation in Adults

The FDA has approved a second indication for plecanatide (Trulance, Synergy Pharmaceuticals Inc.): the once-daily treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Plecanatide was already approved for the treatment of adults with chronic idiopathic constipation (CIC). The 3-mg…

Fixed-Dose Cinqair Misses the Mark in Two Asthma Trials

Two phase 3 studies evaluating a fixed 110-mg subcutaneous dose of reslizumab (Cinqair, Teva Pharmaceutical Industries Ltd.) failed to meet their primary endpoints: reducing exacerbations in patients with uncontrolled asthma in one trial, and reducing oral corticosteroid doses in asthma patients dependent…

Semaglutide Posts Promising Results in Phase 3a Diabetes Trial

Taking a once-daily tablet of semaglutide led to “significant and superior improvements” in long-term blood sugar levels for people with diabetes in the phase 3a PIONEER1 trial, Novo Nordisk announced. PIONEER 1 is the first phase 3a trial of oral semaglutide, a new GLP-1 analogue for the treatment…

Mylan, Revance Pair Up to Create a Biosimilar of Botox

Mylan N.V. and Revance Therapeutics, Inc., are teaming up to develop and market a biosimilar to Allergan’s Botox (onabotulinumtoxinA), the market-leading product in a neuromodulator market with overall sales estimated at $4 billion. The two companies announced a global collaboration and license agreement…

Study: Global Consumption of Antibiotics Skyrockets, Further Driving Drug Resistance

Despite the threat of a global health crisis in antibiotic resistance, worldwide use of antibiotics in humans soared 39% between 2000 and 2015, fueled by dramatic increases in low-income and middle-income countries (LMICs), according to a new study in the Proceedings of the National Academy of Sciences…

Simple Blood Test Spots Dementia Protein

Scientists in Japan and Australia have developed a blood test that can identify people who have high levels of a protein associated with Alzheimer's disease. If confirmed by further research, this long-sought test could help in the increasingly desperate search for therapies that halt the progression…

Search form